An analysis of the HER2 + breast cancer dataset revealed that the level of HER2 mRNA expression is also considerably higher in tumors expressing TP53 PV than in tumors expressing the wild-type TP53 [29]. This evidence concerns the gene ERBB2 and breast cancer.